Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease

Abstract

As innovations in global agricultural production and food trading systems lead to major dietary shifts, high morbidity rates from non-alcoholic fatty liver disease (NAFLD), accompanied by elevated risk of lipid metabolism-related complications, has emerged as a growing problem worldwide. Treatment and prevention of NAFLD and chronic liver disease depends on the availability of safe, effective, and diverse therapeutic agents, the development of which is urgently needed. Supported by a growing body of evidence, considerable attention is now focused on interventional approaches that combines nutraceuticals and functional foods. In this review, we summarize the pathological progression of NAFLD and discuss the beneficial effects of nutraceuticals and the active ingredients in functional foods. We also describe the underlying mechanisms of these compounds in the intervention of NAFLD, including their effects on regulation of lipid homeostasis, activation of signaling pathways, and their role in gut microbial community dynamics and the gut-liver axis. In order to identify novel targets for treatment of lipid metabolism-related diseases, this work broadly explores the molecular mechanism linking nutraceuticals and functional foods, host physiology, and gut microbiota. Additionally, the limitations in existing knowledge and promising research areas for development of active interventions and treatments against NAFLD are discussed.

Keywords: Astaxanthin (PubChem CID: 5281224); Curcumin (PubChem CID: 969516); Functional food; Glycine (PubChem CID: 750); Gut microbiota; Inulin (PubChem CID: 24763); NAFLD; Nutraceutical; Omega-3 polyunsaturated fatty acid (PubChem CID: 56842239); Phytochemical; Resveratrol (PubChem CID: 445154); Serine (PubChem CID: 5951); Silybin (PubChem CID: 31553); Sterol (PubChem CID: 1107); Vitamin A (PubChem CID: 445354).